Recent research has uncovered an unexpected side effect of GLP-1 weight-loss drugs, such as Ozempic and Wegovy. These medications, commonly prescribed for type 2 diabetes and obesity, have been found to cause abnormal patterns in FDG PET-CT scans. This interference could potentially lead to misinterpretations, unnecessary diagnostic tests, and delays in appropriate treatment.
A study conducted by Alliance Medical, a European imaging service provider, reviewed oncologic FDG PET-CT scans in patients using GLP-1 drugs. The researchers observed unusual uptake patterns that could be mistaken for signs of disease if the patient’s medication history is not considered. These findings were presented at the Annual Congress of the European Association of Nuclear Medicine.
Dr. Peter Strouhal, Medical Director at Alliance Medical, emphasized the increasing prevalence of these altered patterns and the lack of national or international guidance addressing this emerging issue. He advised imaging professionals to meticulously document patients’ medication histories to prevent misdiagnosis and ensure appropriate care.
As the use of GLP-1 drugs continues to rise, healthcare providers are urged to be aware of this potential side effect to avoid unnecessary anxiety and interventions for patients undergoing medical imaging.
